Biotech Values

[DewDiligence]

MNTA – It looks like I was a tad early buying back the partial position I sold in March, but I’m not unduly concerned about that. To the contrary, I can sleep easier knowing that I once again have a “full position”; now I don’t have to worry about missing full participation in a VNDA-like pop if and when the FDA approves the Lovenox ANDA from NVS/MNTA and fails to approve the ANDA’s from the other applicants.